Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture.
about
Human telomerase and its regulationEffects of cisplatin on telomerase activity and telomere length in BEL-7404 human hepatoma cellsDown-regulation of telomerase activity in malignant lymphomas by radiation and chemotherapeutic agentsNatural and pharmacological regulation of telomeraseChemistry in human telomere biology: structure, function and targeting of telomere DNA/RNA.Telomerase. A target for anticancer therapy.Telomerase is controlled by protein kinase Calpha in human breast cancer cells.Recent advances in the development of telomerase inhibitors for the treatment of cancer.Telomere maintenance mechanisms as a target for drug development.Telomerase and cancer: time to move from a promising target to a clinical reality.Telomerase inhibitors for the treatment of cancer: the current perspective.Telomere and telomerase in oncology.The tumour suppressor RASSF1A is a novel substrate of PKC.Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugsEndogenous adenosine contributes to renal sympathetic neurotransmission via postjunctional A1 receptor-mediated coincident signaling.Telomere and telomerase as targets for anti-cancer and regeneration therapies.hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cellsUp-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide.Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissuesRole of RACK1 in the differential proliferative effects of neuropeptide Y(1-36) and peptide YY(1-36) in SHR vs. WKY preglomerular vascular smooth muscle cells.Telomerase expression and activity are coupled with myocyte proliferation and preservation of telomeric length in the failing heartChange of the expression of human telomerase reverse transcriptase mRNA and human telomerase RNA after cisplatin and 5-fluorouracil exposure in head and neck squamous cell carcinoma cell lines.Regulation of telomerase activity by alternate splicing of human telomerase reverse transcriptase mRNA in a subset of neuroblastomas.Regulation of phorbol ester-mediated TRAF1 induction in human colon cancer cells through a PKC/RAF/ERK/NF-kappaB-dependent pathway.beta-Adrenoceptor agonist sensitizes the dopamine-1 receptor in renal tubular cells.Cell cycle-dependent regulation of telomerase activity by auxin, abscisic acid and protein phosphorylation in tobacco BY-2 suspension culture cells.Modulation of LPS stimulated NF-kappaB mediated Nitric Oxide production by PKCepsilon and JAK2 in RAW macrophages.Telomerase is regulated by protein kinase C-zeta in human nasopharyngeal cancer cells.Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin.Pro-atherogenic factors induce telomerase inactivation in endothelial cells through an Akt-dependent mechanism.Expression of human telomerase reverse transcriptase in lymphangioleiomyomatosis.4alpha-Phorbol negates the inhibitory effects of phorbol-12-myristate-13-acetate on human cilia and alters the phosphorylation of PKC.Molecular mechanism of the induction of metalloproteinases 1 and 3 in human fibroblasts by basic calcium phosphate crystals. Role of calcium-dependent protein kinase C alpha.Polymerase chain reaction-based enzyme immunoassay for quantitation of telomerase activity: application to colorectal cancers.9-Hydroxyellipticine inhibits telomerase activity in human pancreatic cancer cells.
P2860
Q24533247-9C9DE547-AF23-4B43-884A-528C1E4F8AF3Q28213921-337594B0-AAC6-4A12-83E2-F2562B172438Q28345325-210AE056-6467-4E53-9B9C-F77DC8211C8EQ31038583-9B92EF13-BAD8-49EA-BAD2-41C030B76A5EQ33814333-0EF71D85-2DB5-45AE-84FD-600EF7F7431EQ33833328-4C82047B-DEE3-4E07-A515-2F1FC74231A3Q34068018-4A7A0A32-8FEB-45AF-A096-DE8424917D9EQ34119554-B61F7FB5-41A5-402E-8DF8-C52C205BB21EQ34293590-9202A993-A7EA-4B3C-B164-2C765F08A440Q34464335-1876AF55-3668-495D-B315-28D9BA30D23EQ34481887-01076CA6-AC36-49CA-91C6-40474BD0951FQ34593359-F794FB86-2147-4761-911F-B8DF808D8FF8Q34783040-6A35D2BA-8A78-4339-9F97-CD27FFF9F22CQ34911093-EEA05377-D40E-4D65-A53E-5B55BD91D19BQ35787419-DF524BD7-2BD5-4D6F-9444-B3B65D410F8DQ36103191-36FE6177-9B4D-4C83-AC0F-2E19F01AB4F2Q36614496-EC4FBEB4-597F-4C94-9D26-AB550EF58DC8Q36620959-40D57A2F-A94A-4AB0-AF06-A496B44DA9D9Q36621009-8538A56B-FA57-447D-B799-21A9A4D9D051Q36699796-297F325E-A984-48D8-92F9-1160A0C34101Q37108368-A0661FE5-C988-4301-9D1D-084B08BAEC7BQ37222516-6CCEC2A6-CC83-49D3-8B5B-F93CC20764DFQ38458954-EDC0926F-7FB2-4C96-87E3-8AAEB34AB011Q40586194-607A1035-D8DB-4CB6-ADB9-7D8D47116BA9Q40712277-B61E3CC9-1E4B-4EDB-9484-A0403B093499Q42518112-93D6ABB8-FEE5-40F2-A19D-B913CBBA52BBQ42970545-1BA16275-88D0-4982-A24F-4F2EBC7DD7F3Q42999025-4D9A55AE-C867-435B-AF4B-BCA951D694F8Q43159620-B4520C6E-7A23-4E7C-86B2-6C55EEA31911Q43559008-15D35186-349D-4BC8-9FC8-849C8C3B2245Q44064939-77789AB8-82CC-4996-BEBE-0D87879672EDQ44185049-D872D8D1-8A51-4423-A634-83FD3E9DD5F8Q50336814-CC809A6C-124D-4BE7-9D37-71D96F754F2BQ52212884-7CE41999-AB9D-4052-987E-65332236D497Q53427484-D5D0006A-9B1B-4886-9E3E-8CFDDBD32B87
P2860
Inhibition of telomerase activity by PKC inhibitors in human nasopharyngeal cancer cells in culture.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@en
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@nl
type
label
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@en
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@nl
prefLabel
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@en
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@nl
P2093
P356
P1476
Inhibition of telomerase activ ...... ngeal cancer cells in culture.
@en
P2093
P304
P356
10.1006/BBRC.1997.7874
P407
P577
1997-12-01T00:00:00Z